Drug Registration in Thailand: A 2026 Guide to Thai FDA Approval

Why Drug Registration in Thailand Matters in 2026

Thailand offers pharmaceutical companies a large public health system, a growing private hospital sector, and a strategic base for ASEAN distribution. However, no medicinal product may be sold until the Thai Food and Drug Administration (Thai FDA) approves it. In addition, 2026 marks a turning point. Marketing authorizations issued under the amended Drug Act after October 2019 are valid for only seven years. As a result, the earliest of those authorizations begin to expire from October 2026, and renewal applications must be filed well in advance.

Consequently, both new entrants and established license holders need a clear regulatory strategy this year. New entrants must choose the right registration pathway. Meanwhile, existing holders must audit their portfolios and calendar their renewal deadlines.

The Legal Framework: Drug Act B.E. 2510

The Drug Act B.E. 2510 (1967), as amended, governs medicines in Thailand. Under Section 12, no person may manufacture, sell, or import a modern drug without a license from the Thai FDA, which operates under the Ministry of Public Health. The registration of each drug formula then sits on top of that license: the license authorizes the business activity, while the marketing authorization approves the specific product.

The Drug Act (No. 6) B.E. 2562 (2019), effective 13 October 2019, modernized the regime. Notably, it introduced the seven-year validity period for registrations, updated clinical research provisions, and revised the official fee schedule. Therefore, companies relying on pre-2019 assumptions — especially the old rule that registrations never expired — should update their compliance calendars immediately.

Licenses You Need Before You Apply

Foreign pharmaceutical companies cannot hold a Thai marketing authorization directly from abroad. Instead, the applicant must be a locally licensed entity. In practice, this means one of three routes: establishing a Thai subsidiary that holds an import license, appointing a licensed local distributor as the authorization holder, or contracting a licensed third-party license holder.

Each route has commercial consequences. For example, if the local distributor owns the registration, switching distributors later can require re-registration or a negotiated transfer. Accordingly, many multinationals prefer their own license-holding entity to retain control of the dossier. The choice also interacts with corporate structuring and FDA-related business licensing, so it deserves board-level attention rather than an afterthought.

Registration Pathways and Dossier Requirements

Thailand accepts dossiers in the ASEAN Common Technical Document (ACTD) or ICH CTD format, and new drug applications must now be filed electronically as eCTD submissions. The pathway determines the evidence you must file:

The reliance pathway is often the fastest option for innovative products. Nevertheless, it demands discipline: the two-year window from the benchmark approval closes quickly, so global regulatory teams should plan their Thai filing alongside their US or EU submissions, not after them.

How Long Does Drug Registration in Thailand Take?

Review timelines vary by pathway. According to the Thai FDA’s published service manual, a new drug registration takes approximately 280 working days from a complete submission. Generic products typically move faster, often within six to twelve months. In addition, incomplete dossiers trigger query cycles that can add months, so front-loading quality into the first submission pays for itself.

Official fees depend on the product and evaluation type. As a rough benchmark, application, evaluation, and license fees for a new drug total in the region of THB 190,000, although the exact figure varies with each dossier. Translation, local agent, and bioequivalence study costs come on top of the official fees.

Conditional Approval and the Safety Monitoring Program

Thailand approves new drugs conditionally at first. During this phase, the product may be dispensed only through hospitals and medical clinics, and the license holder must run a Safety Monitoring Program (SMP) for approximately two years. The program requires periodic safety update reports to the Thai FDA, which uses the data to confirm the drug’s safety profile in Thai patients.

After the monitoring period, the company may apply to lift the conditions. Once the Thai FDA grants unconditional approval, the product can move into retail pharmacy channels. Commercially, this matters: launch plans, pricing strategies, and distribution agreements should all reflect the hospital-only phase. Similarly, labeling must comply with Thai FDA requirements from day one — an area where our analysis of Thailand’s labeling rules shows how strictly the regulator polices consumer-facing information.

Data Protection, Exclusivity, and Patents

Thailand has no standalone data exclusivity statute for pharmaceutical registration data. Instead, protection rests on the Trade Secrets Act and a Ministry of Public Health regulation that keeps approved registration information safeguarded as a trade secret for five years from approval. This framework protects the dossier from disclosure. However, it does not prevent the Thai FDA from approving a generic that relies on its own bioequivalence data.

Patent protection therefore remains the primary shield for innovative products, and it runs on a separate track from registration. Furthermore, companies should register their trademarks early, because parallel imports and copycat branding are recurring issues in the Thai market. A coordinated strategy — patents, trademarks, and regulatory filings moving together — closes the gaps that any single protection leaves open.

The Seven-Year Renewal Cycle

Every marketing authorization granted after 13 October 2019 expires seven years from issuance. Renewal applications must be submitted at least one year before expiry, and they must meet the registration requirements current at the time of renewal — not the standards that applied when the product was first approved. In other words, a renewal is a substantive review, not a rubber stamp.

For portfolio holders, the practical steps are clear. First, inventory every Thai registration and its issue date. Second, diary the renewal filing deadline twelve months before each expiry. Third, gap-assess each dossier against current requirements, because older files often lack updated stability data or revised labeling. Companies that treat drug registration in Thailand as a continuing compliance function, rather than a closed file, will avoid the supply interruptions that a lapsed authorization causes. The broader mechanics of dealing with the regulator are covered in our step-by-step guide to the Thailand FDA registration process.

Frequently Asked Questions

Conclusion

Drug registration in Thailand rewards companies that treat it as a strategic discipline. The pathway choice shapes your timeline, the local license holder shapes your control, and the seven-year renewal cycle shapes your long-term compliance budget. With the first renewal deadlines arriving from October 2026, the cost of a passive approach has never been higher. Authoritative guidance is available from the Thai Food and Drug Administration, and manufacturing standards follow the internationally recognized PIC/S GMP framework.